Publications by authors named "Matteo Accinno"
Article Synopsis
- * A new automated surface plasmon resonance (SPR)-based method was developed to track both AAA and ADL without requiring complex sample prep, allowing for multiple analyses with a single chip.
- * In a study with 47 ADL-treated patients, both SPR and ELISA methods detected AAA, achieving a 79% overall agreement, with noted differences in quantitative results, particularly in assessing ADL levels effectively.
Effects of Mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study.
Eur Arch Otorhinolaryngol
October 2024
Purpose: Mepolizumab was recently approved for treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) unresponsive to standard treatment or recurring after endoscopic sinus surgery (ESS). To date, few studies have assessed Mepolizumab's efficacy in severe type-2 CRSwNP. Our study aimed to analyze sinonasal outcomes in type-2 CRSwNP patients treated with 100 mg Mepolizumab administered subcutaneously every four weeks.
View Article and Find Full Text PDFBackground: Eosinophils have been divided into different subpopulations with distinct phenotypes based on CD62L expression. No data are available regarding the correlation between eosinophils subphenotypes and clinical severity of asthma, as well as the effect of anti-IL-5 therapy on these cells. The study investigates the correlation between blood CD62L inflammatory eosinophils (iEos) and clinical severity of severe eosinophilic asthma (SEA) and evaluates the impact of mepolizumab on iEos.
View Article and Find Full Text PDFIntroduction: Asthma is a chronic inflammatory disease that can lead to airways remodeling. Despite their well-known side-effects, oral corticosteroids (OCS) continue to be used to reduce exacerbations and control asthma symptoms in many patients.
Case Study: We describe two cases of uncontrolled severe asthma characterized by systemic clinical consequences of prolonged OCS use, such as diabetes, weight gain, and osteoporosis.
Background: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a small-vessel necrotizing vasculitis. The anti-neutrophil cytoplasmic antibodies' (ANCA) role in defining clinical EGPA phenotypes is well established. Although the role of eosinophils in disease pathogenesis has been clearly demonstrated, the value of blood eosinophil count (BEC) as a biomarker of disease phenotypes is currently uncertain.
View Article and Find Full Text PDFBackground: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel necrotizing vasculitis with multiple organ involvement. Despite improvements in clinical management, biomarkers for organ involvement and disease prognosis are still an unmet need. Methods: EGPA patients referred to our immunology clinic were retrospectively reviewed.
View Article and Find Full Text PDFArticle Synopsis
- Eosinophils, important immune cells, are categorized into distinct subpopulations in mice based on their surface markers, but there’s limited research on these distinctions in humans, particularly in eosinophilic asthma patients.
- The study focused on analyzing eosinophil subpopulations in the peripheral blood and nasal polyp tissue of patients with severe eosinophilic asthma who also have chronic rhinosinusitis, comparing them to various control groups.
- Results revealed that severe eosinophilic asthma patients had a higher percentage of a specific eosinophil subtype (CD62L) in both blood and nasal tissues, indicating a unique accumulation pattern and functional differences in these cells between the two environments.